← FDA DRUG APPROVALS

FDA ANDA · ANDA208709

FENOFIBRATE

Sponsor: CIPLA

APPLICATION
ANDA208709
TYPE
ANDA
ORIGINAL APPROVAL
2016-12-15
LATEST ACTION
2025-08-21
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

FENOFIBRATEPrescription
FENOFIBRATE 48MG · TABLET · ORAL
FENOFIBRATEPrescription
FENOFIBRATE 145MG · TABLET · ORAL

Approval history

2025-08-21Labeling · Supplement 11 · standardAP
2022-05-27Labeling · Supplement 6 · standardAP
2019-09-19Labeling · Supplement 5 · standardAP
2019-09-19Labeling · Supplement 3 · standardAP
2019-09-19Labeling · Supplement 2 · standardAP
2016-12-15UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →